The global women’s health market size is expected to reach USD 68.53 billion by 2030, registering a CAGR of 5.1% from 2025 to 2030. The introduction of innovative novel products and the presence of a strong pipeline of women’s health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.
For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.
For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.
For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women’s health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.
For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.
For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.
For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women’s health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.
Women's Health Market Report Highlights
- The contraceptives segment held the highest revenue share of more than 35.07% of the global revenue in 2024, spurred by rising awareness of family planning and ongoing technological advancements in contraceptive methods.
- Hormonal therapies segment led the market in 2024 and is expected to grow at fastest growth rate over the forecast period.
- The others (below 50 years) segment dominated the market in 2024 and is expected to sustain the position for the forecast period. Women aged below 50 years are more likely to face issues associated with fertility, such as endometriosis, hormonal infertility, and polycystic ovary syndrome.
- The North America women’s health market dominated the global market with a share of 43.04% in 2024.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Women’s Health Market Variables, Trends & Scope
Chapter 4. Women’s Health Market: Application Estimates & Trend Analysis
Chapter 5. Women’s Health Market: Drug Class Estimates & Trend Analysis
Chapter 6. Women’s Health Market: Age Estimates & Trend Analysis
Chapter 7. Women’s Health Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- AbbVie, Inc.
- Bayer AG
- Organon & Co.
- Pfizer, Inc.
- Theramex
- Agile Therapeutics
- Amgen, Inc.
- Apothecus Pharmaceutical Corp.
- Blairex Laboratories, Inc.
- Ferring
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | November 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 49.33 Billion |
| Forecasted Market Value ( USD | $ 68.53 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
